



4 June 2024

cyclo**medica**
tech**ne**gas
ultra**lute**

Cyclopharm Ltd
ABN 74 116 931 250
Unit 4, 1 The Crescent
Kingsgrove NSW 2208 Australia
T 61 2 9541 0411
F 61 2 9543 0960
www.cyclopharm.com.au

NOTICE UNDER SECTION 708A(5) OF THE CORPORATIONS ACT 2001 (CTH)

On 24 May 2024, Cyclopharm Limited (the “**Company**”) announced a placement (“**Placement**”) of approximately 14.1 million new fully paid ordinary shares at \$1.42 per share (“**Placement Shares**”) raising approximately A\$20.0 million before costs.

On 30 May 2024, the Company issued 11,971,832 Placement Shares under the Placement. Cyclopharm is pleased to advise that it has today issued 2,112,676 Placement Shares being the balance of the Placement Shares to be issued under the Placement (“**Tranche 2 Shares**”).

Accordingly, the Company advises:

- 1 The Tranche 2 Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act 2001 (Cth) (the “**Act**”).
- 2 This notice is is being given under section 708A(5)(e) of the Act.
- 3 As at the date of this notice, the Company has complied with:
 - (a) the provisions of Chapter 2M of the Act as they apply to the Company; and
 - (b) sections 674 and 674A of the Act.
- 4 As at the date of this notice, there is no excluded information as defined in sections 708A(7) and 708A(8) of the Act which is required to be disclosed by the Company.

This ASX announcement was approved and authorised for release by James McBrayer, Managing Director, CEO and Company Secretary.

For more information, please contact:

Mr James McBrayer
Managing Director, CEO and Company Secretary
Cyclopharm Limited
T: +61 (02) 9541 0411